Human Disease Model Report: cancer, epithelial, EGFR-microRNA-related

General Information

Name

cancer, epithelial, EGFR-microRNA-related

FlyBase ID

FBhh0000398

Disease Ontology Term

carcinoma

Parent Disease

OMIM

Overview

Human epidermal growth factor receptor (EGFR) has been implicated in multiple cancers of epithelial derivation. EGFR is a transmembrane receptor kinase that spans the cell membrane and is activated by a number of external ligands, including EGF and transforming growth factor α. Activation of EGFR initiates several signal transduction cascades, leading to DNA synthesis and cell proliferation. There is one orthologous gene in flies, Dmel\Egfr, for which classical amorphic and hypomorphic alleles, constitutively active alleles, RNAi-targeting constructs, and alleles caused by insertional mutagenesis have been generated. Dmel\Egfr is orthologous to three additional human genes, ERBB4, ERBB3 and ERBB2. ERBB2 has also been implicated in multiple cancers.

When Dmel\Egfr overexpression in imaginal disc epithelial cells is combined with expression of specific microRNAs (mir-ban, mir-8, mir-10 and mir-375), much more severe phenotypes are observed, including loss of apico-basal polarity and loss of epithelial organization, indicating an epithelial to mesenchymal transition. Reducing expression of one of the genes postulated to be the downstream regulatory targets of the microRNAs (for example, Socs36E and psq), in combination with Dmel\Egfr overexpression also results in more severe phenotypes; metastatic phenotypes are observed. See the human disease model reports 'cancer, epithelial, EGFR-Dmel\psq model' (FBhh0000933) and 'cancer, epithelial, EGFR-SOCS-related' (FBhh0000934).

Amorphic mutations of Dmel\Egfr act as recessive embryonic lethals; they also act as cell lethals in somatic clones. Hypermorphic (gain-of-function) alleles exhibit dominant visible phenotypes. Egfr overexpression in imaginal disc epithelial cells leads to mild overproliferation phenotypes. Extensive physical and genetic interactions have been described; see below and in the gene report for Egfr. See the human disease model report 'cancer, epithelial, EGFR-related' (FBhh0000932).

The human gene Hsap\EGFR has been introduced into flies, using a mutant form that displays constitutive kinase activity and can be expressed in specific tissues using the GAL4-UAS system. Constructs of Hsap\EGFR have been used for human disease models of malignant glioma (FBhh0000399, FBhh0000401, FBhh0000403).

[updated Dec. 2018 by FlyBase; FBrf0222196]

Disease Summary Information

Disease Summary: cancer, epithelial, EGFR-microRNA-related

OMIM report

Human gene(s) implicated

Symptoms and phenotype

Genetics

Epidermal growth factor receptor (EGFR) has been implicated in multiple cancers, including non-small-cell lung cancer (MIM:211980). [from MIM:131550; 2016.09.30]

(OMIM, 2013-)

Cellular phenotype and pathology

Molecular information

Epidermal Growth Factor Receptor (EGFR) is a transmembrane receptor tyrosine kinase of the ErbB family. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Binding of DGFR can activate at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. [from Gene Cards, EGFR; 2016.09.30]

(FlyBase Curators, 2013-)

External links

Gene2Function (human gene): EGFR
Gene Cards: EGFR
MedlinePlus (gene): EGFR
KEGG Disease Pathways: Pathways in Cancer
MARRVEL (human gene): EGFR
NCBI (Entrez) gene: EGFR; epidermal growth factor receptor

Disease synonyms

cancer, multiple, EGFR-related

Search term: metastatic phenotype(s)

Search term: neoplastic phenotype(s)

Related Diseases

Related human health report(s)

cancer, epithelial, EGFR-Dmel\psq model

cancer, epithelial, EGFR-related

cancer, epithelial, EGFR-SOCS-related

cancer, malignant glioma, EGFR-MYC-related

cancer, malignant glioma, EGFR-related

Ortholog Information

Human gene(s) in FlyBase

Hsap\EGFR

Human gene (HGNC)

Symbol / Name

EGFR; epidermal growth factor receptor

D. melanogaster ortholog (based on DIOPT)

Dmel\Egfr

(DIOPT, 2013-)

Comments on ortholog(s)

Many to one (4 human to 1 Drosophila); additional human orthologs are ERBB4, ERBB3, and ERBB2.

Other mammalian ortholog(s) used

D. melanogaster Gene Information (5)

Dmel\Egfr

Gene Snapshot

Epidermal growth factor receptor (Egfr) encodes the transmembrane tyrosine kinase receptor for signaling ligands (encoded by grk, spi, vn, and Krn) in the TGFα family, which utilises the intracellular MAP kinase pathway. The product of Egfr contributes to growth regulation, cell survival and developmental patterning. [Date last reviewed: 2019-06-06]

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

EGFR-C
RTK

Comments on ortholog(s)

Orthologous to human genes EGFR, ERBB4, ERBB3, and ERBB2 (1 Drosophila to 4 human). Dmel\Egfr shares 33-37% identity and 46-51% similarity with the human genes.

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\mir-ban

Gene Snapshot

Contributions welcome

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

5' seed sequence homologous to that of human MIR450B-3p (FBrf0242402).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\mir-8

Gene Snapshot

Contributions welcome

Molecular function (GO)

Cellular component (GO)

RISC complex

Gene Groups / Pathways

Comments on ortholog(s)

Orthologous to human MIR429, MIR200B, MIR200C and others (FBrf0242402).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\mir-10

Gene Snapshot

Contributions welcome

Molecular function (GO)

mRNA base-pairing post-transcriptional repressor activity

Cellular component (GO)

RISC complex

Gene Groups / Pathways

HH-SMON

Comments on ortholog(s)

Orthologous to human MIR10A and MIR10B (FBrf0242402).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\mir-375

Gene Snapshot

Contributions welcome

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

Orthologous to human MIR375 (FBrf0242402).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Other Genes Used: Viral, Bacterial, Synthetic (0)

Summary of Physical Interactions (110 groups)

Egfr

RNA-protein

Interacting group

Assay

References

Egfr - Fmr1

anti bait coimmunoprecipitation, quantitative reverse transcription pcr, clip-seq

(Buddika et al., 2021)

Egfr - pum

rna three hybrid

(Kim et al., 2012)

protein-protein

Interacting group

Assay

References

Egfr

solid phase assay, tag visualisation by fluorescence, anti tag coimmunoprecipitation, anti tag western blot

(Alvarado et al., 2010, Alvarado et al., 2004)

Egfr - Abi

anti bait coimmunoprecipitation, western blot

(Stephan et al., 2008)

Egfr - Abl

two hybrid

(Bianco et al., 2007)

Egfr - arm

anti bait coimmunoprecipitation, western blot

(Dumstrei et al., 2002)

Egfr - ATPsynβ

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Egfr - aux

anti tag coimmunoprecipitation, western blot, anti bait coimmunoprecipitation

(Zhao et al., 2022)

Egfr - Btk

two hybrid

(Bianco et al., 2007)

Egfr - Cbl

pull down, anti tag western blot, anti tag coimmunoprecipitation, western blot

(Kim et al., 2017, Hime et al., 1997, Meisner et al., 1997)

Egfr - CG10916

anti tag coimmunoprecipitation, peptide massfingerprinting, anti tag western blot

(Friedman et al., 2011, Friedman et al., 2011)

Egfr - Crk

two hybrid

(Bianco et al., 2007)

Egfr - dock

two hybrid

(Bianco et al., 2007)

Egfr - drk

two hybrid, anti tag coimmunoprecipitation, peptide massfingerprinting, anti bait coimmunoprecipitation, western blot, pull down

(Friedman et al., 2011, Wang and Pai, 2011, Bianco et al., 2007, MacDougall et al., 2004, Lai et al., 1995, Schweitzer et al., 1995)

Egfr - Egfrap

two hybrid

(Soler Beatty et al., 2021, Bianco et al., 2007)

Egfr - Fas2

anti bait coimmunoprecipitation, anti tag western blot, anti tag coimmunoprecipitation, western blot

(Velasquez et al., 2022)

Egfr - Graf

anti tag coimmunoprecipitation, western blot, pull down, anti tag western blot

(Kim et al., 2017)

Egfr - Hsp83

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Egfr - kek1

enzyme linked immunosorbent assay, anti tag coimmunoprecipitation, western blot, anti tag western blot

(Ozkan et al., 2013, Alvarado et al., 2004, Alvarado et al., 2004, Derheimer et al., 2004, Ghiglione et al., 2003)

Egfr - Lnk

two hybrid

(Bianco et al., 2007)

Egfr - Mbs

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Egfr - Mcad

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Egfr - Pi3K21B

two hybrid

(Bianco et al., 2007)

Egfr - porin

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Egfr - Ptp10D

anti tag coimmunoprecipitation, anti tag western blot

(Jeon and Zinn, 2009)

Egfr - Pyk

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Egfr - RFeSP

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Egfr - Sec10

pull down, anti tag western blot, anti tag coimmunoprecipitation, western blot

(Mao et al., 2019)

Egfr - Sec15

anti tag coimmunoprecipitation, anti tag western blot, pull down, western blot

(Mao et al., 2019)

Egfr - Shc

pull down, western blot, anti tag coimmunoprecipitation, anti tag western blot, anti bait coimmunoprecipitation, two hybrid

(Bianco et al., 2007, van der Geer et al., 1996, Lai et al., 1995)

Egfr - shg

anti bait coimmunoprecipitation, western blot

(Dumstrei et al., 2002)

Egfr - spi

cosedimentation in solution, solid phase assay, tag visualisation by fluorescence, surface plasmon resonance, x-ray crystallography, predetermined participant

(Alvarado et al., 2010, Miura et al., 2006, Klein et al., 2004)

Egfr - sqd

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Egfr - Src42A

two hybrid

(Bianco et al., 2007)

Egfr - vap

anti tag coimmunoprecipitation, anti tag western blot, two hybrid

(Rowshanravan et al., 2014, Bianco et al., 2007)

Egfr - Vav

anti bait coimmunoprecipitation, western blot, two hybrid, anti tag coimmunoprecipitation, peptide massfingerprinting

(Fernández-Espartero et al., 2013, Friedman et al., 2011, Bianco et al., 2007, Sarkar et al., 2007)

mir-ban

RNA-protein

Interacting group

Assay

References

mir-ban - AGO1

anti bait coimmunoprecipitation, northern blot, anti tag coimmunoprecipitation, filter binding, competition binding, autoradiography, pull down, western blot, nuclease footprinting

(Kakumani et al., 2020, Wen et al., 2015, Yang et al., 2014, Carré et al., 2013, Hur et al., 2013, Nishida et al., 2013, Eulalio et al., 2009, Flynt et al., 2009, Miyoshi et al., 2009, Eulalio et al., 2008, Zhou et al., 2008, Förstemann et al., 2007, Rehwinkel et al., 2006, Miyoshi et al., 2005, Okamura et al., 2004)

mir-ban - AGO2

anti tag coimmunoprecipitation, northern blot, filter binding, autoradiography

(Yang et al., 2014, Hur et al., 2013, Rehwinkel et al., 2006, Okamura et al., 2004)

mir-ban - bel

anti tag coimmunoprecipitation, northern blot

(Zhou et al., 2008)

mir-ban - Dcr-1

anti tag coimmunoprecipitation, northern blot, electrophoretic mobility shift assay, autoradiography, enzymatic study

(Liu et al., 2007, Ye et al., 2007, Saito et al., 2005)

mir-ban - drosha

enzymatic study, northern blot

(Denli et al., 2004)

mir-ban - Fmr1

anti tag coimmunoprecipitation, northern blot, anti bait coimmunoprecipitation, quantitative reverse transcription pcr

(Yang et al., 2009, Okamura et al., 2004)

mir-ban - gw

anti tag coimmunoprecipitation, northern blot, anti bait coimmunoprecipitation

(Eulalio et al., 2009, Eulalio et al., 2009, Miyoshi et al., 2009, Zekri et al., 2009)

mir-ban - His1

anti tag coimmunoprecipitation, quantitative reverse transcription pcr

(Liu et al., 2016)

mir-ban - loqs

fluorescence polarization spectroscopy, predetermined participant, anti tag coimmunoprecipitation, northern blot, anti bait coimmunoprecipitation

(Tants et al., 2017, Miyoshi et al., 2009, Saito et al., 2005)

mir-ban - pasha

enzymatic study, northern blot

(Denli et al., 2004)

mir-ban - Ran

anti tag coimmunoprecipitation, northern blot

(Zhou et al., 2008)

mir-ban - ref(2)P

anti tag coimmunoprecipitation, quantitative reverse transcription pcr

(Ghosh et al., 2024)

mir-ban - RpL21

anti tag coimmunoprecipitation, northern blot

(Zhou et al., 2008)

mir-ban - RpL22

anti tag coimmunoprecipitation, northern blot

(Zhou et al., 2008)

mir-ban - RpL32

anti tag coimmunoprecipitation, northern blot

(Zhou et al., 2008)

mir-ban - RpS7

anti tag coimmunoprecipitation, northern blot

(Zhou et al., 2008)

mir-ban - SmD1

anti bait coimmunoprecipitation, primer specific pcr

(Xiong et al., 2015)

mir-ban - Unr

pull down, western blot

(Kakumani et al., 2020)

mir-ban - vig

anti tag coimmunoprecipitation, northern blot

(Zhou et al., 2008)

RNA-RNA

Interacting group

Assay

References

mir-ban - cic

luminiscence technology, necessary binding region

(Herranz et al., 2012)

mir-ban - Clk

luminiscence technology, necessary binding region

(Kadener et al., 2009)

mir-ban - hid

luminiscence technology, fluorescence technology, necessary binding region, immunohistochemistry

(Shen et al., 2015, Kertesz et al., 2007, Leaman et al., 2005, Robins et al., 2005, Brennecke et al., 2003)

mir-ban - Mad

luminiscence technology, necessary binding region

(Robins et al., 2005)

mir-ban - mei-P26

immunohistochemistry, luminiscence technology, necessary binding region

(Herranz et al., 2010)

mir-ban - numb

luminiscence technology, necessary binding region

(Wu et al., 2017)

mir-ban - Tgi

western blot, luminiscence technology, necessary binding region, immunohistochemistry

(Shen et al., 2015)

mir-ban - trbl

fluorescence technology

(Gerlach et al., 2019)

mir-8

RNA-protein

Interacting group

Assay

References

mir-8 - AGO1

anti bait coimmunoprecipitation, northern blot, pull down, western blot

(Kakumani et al., 2020, Lim et al., 2020)

mir-8 - AGO2

anti tag coimmunoprecipitation, northern blot

(Abe et al., 2014)

mir-8 - Dcr-1

enzymatic study, autoradiography

(Tsutsumi et al., 2011)

mir-8 - Fmr1

anti bait coimmunoprecipitation, quantitative reverse transcription pcr

(Yang et al., 2009)

mir-8 - His1

anti tag coimmunoprecipitation, quantitative reverse transcription pcr

(Liu et al., 2016)

mir-8 - loqs

fluorescence polarization spectroscopy, predetermined participant

(Tants et al., 2017)

mir-8 - Rox8

anti tag coimmunoprecipitation, quantitative reverse transcription pcr

(Guo et al., 2020)

mir-8 - SmD1

anti bait coimmunoprecipitation, primer specific pcr

(Xiong et al., 2015)

mir-8 - SmD2

anti tag coimmunoprecipitation, primer specific pcr

(Xiong et al., 2015)

mir-8 - Unr

pull down, western blot

(Kakumani et al., 2020)

RNA-RNA

Interacting group

Assay

References

mir-8 - Adgf-A

quantitative reverse transcription pcr

(Lee et al., 2015)

mir-8 - Adgf-B

quantitative reverse transcription pcr

(Lee et al., 2015)

mir-8 - ATP6AP2

luminiscence technology, quantitative reverse transcription pcr

(Lim et al., 2020)

mir-8 - caly

luminiscence technology

(Hyun et al., 2009)

mir-8 - Ced-12

luminiscence technology

(Hyun et al., 2009)

mir-8 - CG8420

quantitative reverse transcription pcr

(Karres et al., 2007)

mir-8 - CG13060

quantitative reverse transcription pcr

(Karres et al., 2007)

mir-8 - CG32767

luminiscence technology, necessary binding region

(Kennell et al., 2008)

mir-8 - Cpr56F

quantitative reverse transcription pcr

(Karres et al., 2007)

mir-8 - dbo

luminiscence technology

(Hyun et al., 2009)

mir-8 - dl

quantitative reverse transcription pcr, luminiscence technology

(Lee and Hyun, 2014)

mir-8 - ena

immunohistochemistry, fluorescence technology, necessary binding region

(Loya et al., 2014)

mir-8 - Gug

quantitative reverse transcription pcr, luminiscence technology, necessary binding region

(Karres et al., 2007)

mir-8 - Idgf1

quantitative reverse transcription pcr

(Lee et al., 2015)

mir-8 - Idgf2

quantitative reverse transcription pcr

(Lee et al., 2015)

mir-8 - Idgf3

quantitative reverse transcription pcr

(Lee et al., 2015)

mir-8 - Idgf6

quantitative reverse transcription pcr

(Lee et al., 2015)

mir-8 - Ilp6

quantitative reverse transcription pcr

(Lee et al., 2015)

mir-8 - ImpL2

quantitative reverse transcription pcr

(Lee et al., 2015)

mir-8 - Lap1

luminiscence technology

(Hyun et al., 2009)

mir-8 - Lar

luminiscence technology

(Nesler et al., 2013, Hyun et al., 2009)

mir-8 - pan

western blot

(Kennell et al., 2008)

mir-8 - pnut

immunohistochemistry

(Eichenlaub et al., 2016)

mir-8 - sd

fluorescence technology

(Sander et al., 2018)

mir-8 - Ser

luminiscence technology, necessary binding region, immunohistochemistry, fluorescence technology

(Vallejo et al., 2011)

mir-8 - spi

quantitative reverse transcription pcr, fluorescence technology, luminiscence technology, necessary binding region

(Morante et al., 2013)

mir-8 - Tl

quantitative reverse transcription pcr, luminiscence technology

(Lee and Hyun, 2014)

mir-8 - ush

luminiscence technology, western blot, quantitative reverse transcription pcr

(Lee and Hyun, 2014, Hyun et al., 2009)

mir-8 - Vha26

western blot, luminiscence technology, quantitative reverse transcription pcr

(Lim et al., 2020)

mir-8 - Vha55

luminiscence technology, western blot, quantitative reverse transcription pcr

(Lim et al., 2020)

mir-8 - Vha100-2

luminiscence technology, quantitative reverse transcription pcr

(Lim et al., 2020)

mir-8 - VhaAC45

quantitative reverse transcription pcr, luminiscence technology

(Lim et al., 2020)

mir-8 - Wdr37

luminiscence technology

(Hyun et al., 2009)

mir-8 - wg

luminiscence technology

(Nesler et al., 2013)

mir-8 - wls

luminiscence technology, necessary binding region, immunohistochemistry

(Kennell et al., 2008)

mir-8 - yki

fluorescence technology

(Sander et al., 2018)

mir-10

RNA-protein

Interacting group

Assay

References

mir-10 - AGO1

anti bait coimmunoprecipitation, northern blot

(Lim et al., 2020, Okamura et al., 2008)

Alleles Reported to Model Human Disease (Disease Ontology) (31 alleles)

Egfr

Models Based on Experimental Evidence ( 6 )

Allele

Disease

Evidence

References

Egfr^2.A887T.UAS

model of intestinal cancer

CEA

(Nászai et al., 2021)

model of cancer

CEA with scrib⁶⁷³

(Sheng and Du, 2020)

CEA

(Brás et al., 2021)

Egfr^UAS.cBa

model of carcinoma

CEA with Socs36E^GD8929

(Xu et al., 2022, Groth et al., 2020, Herranz et al., 2012)

CEA with mir-ban^C.UAS.EGFP

(Herranz et al., 2012)

CEA with Socs36E^EY11

(Herranz et al., 2012)

CEA

(Groth et al., 2020)

CEA with psq^KK111691

(Boukhatmi et al., 2020, Fereres et al., 2019)

model of cancer

CEA with psq^KK111691

(Herranz et al., 2014)

CEA with mir-8^UAS.cUa

(Eichenlaub et al., 2016)

CEA with mir-ban^UAS.cUa

(Eichenlaub et al., 2016)

CEA with Aldh7A1^KK109006

(Andrejeva et al., 2018)

DOES NOT model carcinoma

CEA with Diap1^UAS.cUa

(Herranz et al., 2012)

model of alcohol use disorder

CEA

(Corl et al., 2009)

model of intestinal cancer

CEA

(Nászai et al., 2021)

Egfr^U.A887T.UAS

model of cardiomyopathy

CEA

(Yu et al., 2013)

Egfr^GD1654

model of alcohol use disorder

CEA

(Corl et al., 2009)

Egfr^KK100051

model of renal fibrosis

CEA with DopEcR^KK111211

(Zheng et al., 2020)

Egfr^Act.cUa.UAS

model of high grade glioma

CEA with Pi3K92E^CAAX.UAS

(Pryszlak et al., 2021)

Modifiers Based on Experimental Evidence ( 16 )

Allele

Disease

Interaction

References

Egfr^{FRT.RNAi.slbo}

ameliorates Parkinson's disease 1

modeled by Hsap\SNCA^UAS.cJa

(Rousseaux et al., 2018)

Egfr^1.UAS

exacerbates cancer

modeled by Myc^UAS.cZa, p53^{RNAi.UAS.RasG12D}

(Diaz et al., 2024)

Egfr^2.A887T.UAS

model of intestinal cancer

is ameliorated by Rala^KK108989

(Nászai et al., 2021)

is exacerbated by Rala^UAS.cRa

(Nászai et al., 2021)

Egfr^2.UAS

exacerbates cancer

modeled by Ras85D^{G12V.UAS.Tag:FLAG,Tag:polyHis}

(Washington et al., 2020)

modeled by Ras85D^{Y4F.G12V.UAS.Tag:FLAG,Tag:polyHis}

(Washington et al., 2020)

Egfr^DN.UAS

ameliorates gastrointestinal system cancer

modeled by Apc2^g10, Apc^Q8

(Wang et al., 2013)

ameliorates colorectal cancer

modeled by Src64B^UAS.cCa

(Cordero et al., 2014)

ameliorates carcinoma

modeled by scrib¹

(Brumby and Richardson, 2003)

Egfr^UAS.cBa

ameliorates spinocerebellar ataxia 13

modeled by Hsap\KCNC3^R423H.UAS

(Khare et al., 2017)

model of intestinal cancer

is exacerbated by Rala^UAS.cRa

(Nászai et al., 2021)

is ameliorated by Ras85D^KK108029

(Nászai et al., 2021)

is ameliorated by Rala^KK108989

(Nászai et al., 2021)

Egfr^f2

exacerbates germ cell cancer

modeled by sfl^HMS00543

(Levings and Nakato, 2018)

Egfr^f24

ameliorates Billuart-type X-linked syndromic intellectual developmental disorder

modeled by Graf¹

(Kim et al., 2021)

Egfr^t1

ameliorates colorectal cancer

modeled by Src42A^CA.UAS

(Cordero et al., 2014)

Egfr^JF01368

ameliorates colorectal cancer

modeled by SH3PX1^HMJ21552

(Zhang et al., 2019)

ameliorates glioblastoma

modeled by Pi3K92E^CAAX.UAS, btl::Egfr^λ.UAS

(Chi et al., 2019)

Egfr^UAS.cUa

exacerbates Alzheimer's disease 1

modeled by Hsap\APP^{Aβ42.UAS.cUa}

(Cheng et al., 2021)

Egfr^GD1654

ameliorates prostate cancer

modeled by Ras85D^V12.UAS

(Rambur et al., 2020)

Egfr^KK100051

ameliorates colorectal cancer

modeled by Src42A^CA.UAS

(Cordero et al., 2014)

exacerbates alcohol use disorder

modeled by DopEcR^c02142

(Petruccelli et al., 2016)

Egfr^DN.cUa.UAS

DOES NOT ameliorate cancer

modeled by Hipk^UAS.Tag:HA

(Blaquiere et al., 2018)

Egfr^JF02283

ameliorates lung adenocarcinoma

modeled by Hsap\KIF5B::Hsap\RET^UAS.cDa

(Das and Cagan, 2017)

Egfr^RNAi.UAS.cUa

ameliorates intestinal cancer

modeled by Src64B^UAS.cUa

(Kohlmaier et al., 2015)

modeled by Src42A^CA.UAS

(Kohlmaier et al., 2015)

mir-ban

Models Based on Experimental Evidence ( 2 )

Allele

Disease

Evidence

References

mir-ban^C.UAS.EGFP

model of carcinoma

CEA with Egfr^UAS.cBa

(Herranz et al., 2012)

model of cancer

CEA with Rab5^LL00467

(Cong et al., 2021)

mir-ban^UAS.cUa

model of cancer

CEA with Egfr^UAS.cBa

(Eichenlaub et al., 2016)

Modifiers Based on Experimental Evidence ( 7 )

Allele

Disease

Interaction

References

mir-ban^{sponge.UAS.DsRed(Unk)}

ameliorates carcinoma

modeled by Ras85D^V12.UAS, l(2)gl⁴

(Ito and Igaki, 2021)

mir-ban^D.UAS.EGFP

ameliorates neurodegenerative disease

modeled by Hsap\ATXN3^{tr.Q78.UAS.Tag:HA}

(Bilen et al., 2006)

mir-ban^B90.1

ameliorates neurodegenerative disease

modeled by Hsap\ATXN3^{tr.Q78.UAS.Tag:HA}

(Bilen et al., 2006)

mir-ban^EP3208

exacerbates neurodegenerative disease

modeled by Hsap\ATXN3^{tr.Q78.UAS.Tag:HA}

(Bilen et al., 2006)

mir-ban^C.UAS.EGFP

ameliorates neurodegenerative disease

modeled by Zzzz\CAG^{127Q.UAS.Tag:HA}

(Dubey and Tapadia, 2018)

mir-ban^Δ.as.B.UAS

exacerbates neurodegenerative disease

modeled by Hsap\ATXN3^{tr.Q78.UAS.Tag:HA}

(Bilen et al., 2006)

mir-ban^EP3622

exacerbates neurodegenerative disease

modeled by Hsap\ATXN3^{tr.Q78.UAS.Tag:HA}

(Bilen et al., 2006)

mir-8

Models Based on Experimental Evidence ( 1 )

Allele

Disease

Evidence

References

mir-8^UAS.cUa

model of cancer

CEA with Egfr^UAS.cBa

(Eichenlaub et al., 2016)

Modifiers Based on Experimental Evidence ( 3 )

Allele

Disease

Interaction

References

mir-8^{UAS.DsRed(Unk)}

ameliorates high grade glioma

modeled by Pi3K92E^{UAS.Tag:MYC,Tag:PM(hKRAS)}, btl::Egfr^λ.UAS

(Jarabo et al., 2021)

mir-8^SC1

ameliorates cancer

modeled by lola^GS88A8, psq^GS88A8

(Vallejo et al., 2011)

mir-8^UAS.cVa

ameliorates cancer

modeled by lola^GS88A8, psq^GS88A8

(Vallejo et al., 2011)

Hsap\EGFR

Models Based on Experimental Evidence ( 1 )

Allele

Disease

Evidence

References

Hsap\EGFR^Δ.UAS

model of brain glioma

CEA with Pi3K92E^{UAS.Tag:MYC,Tag:PM(hKRAS)}

(Read et al., 2013)

CEA

(Read et al., 2013)

model of high grade glioma

CEA with Pi3K92E^{UAS.Tag:MYC,Tag:PM(hKRAS)}

(Formica et al., 2021, Terrasi et al., 2019)

Modifiers Based on Experimental Evidence ( 1 )

Allele

Disease

Interaction

References

Hsap\EGFR^Δ.UAS

model of brain glioma

is ameliorated by RIOK1^GD8541

(Read et al., 2013)

is ameliorated by RIOK2^KK101850

(Read et al., 2013)

is ameliorated by RIOK1^KK100810

(Read et al., 2013)

is ameliorated by RIOK2^GD7407

(Read et al., 2013)

Alleles Representing Disease-Implicated Variants

Genetic Tools, Stocks and Reagents

Sources of Stocks

Contact lab of origin for a reagent not available from a public stock center.

Bloomington Stock Center Disease Page

Related mammalian, viral, bacterial, or synthetic transgenes

Allele

Transgene

Publicly Available Stocks

Hsap\EGFR^Δ.UAS

P{UAS-hEGFR.Delta}

Selected Drosophila transgenes

Allele

Transgene

Publicly Available Stocks

y¹ w^*; P{UAS-Egfr.B}32-26-1

Egfr^2.UAS

P{Egfr.2.UAS}

w^*; P{Egfr.2.UAS}7-10

Egfr^2.A887T.UAS

P{Egfr.2.A887T.UAS}

w^*; P{Egfr.2.A887T.UAS}8-2

mir-8^{UAS.DsRed(Unk)}

P{UAS-DsRed-mir-8.L}

w^*; P{UAS-DsRed-mir-8.L}3/TM3, Sb¹

mir-ban^UAS.cUa

P{UAS-mir-ban.U}

mir-ban^D.UAS.EGFP

P{UAS-EGFP-mir-ban.D}

mir-ban^C.UAS.EGFP

P{UAS-EGFP-mir-ban.C}

w^*; P{UAS-EGFP-mir-ban.C}3

mir-ban^Δ.as.B.UAS

P{UAS-mir-ban.Delta.as.B}

mir-ban^{sponge.UAS.DsRed(Unk)}

P{UAS-dsRed.mir-ban.sponge}

RNAi constructs available

Allele

Transgene

Publicly Available Stocks

Egfr^{RNAi.13xlexAop.cZa}

P{13xlexAop-Egfr.RNAi.Z}

w¹¹¹⁸; P{GD1654}v43267

Egfr^JF01368

P{TRiP.JF01368}

y¹ v¹; P{TRiP.JF01368}attP2

y¹ v¹; P{TRiP.JF01083}attP2

Egfr^JF01084

P{TRiP.JF01084}

y¹ v¹; P{TRiP.JF01084}attP2

Egfr^JF01696

P{TRiP.JF01696}

y¹ v¹; P{TRiP.JF01696}attP2

y¹ v¹; P{TRiP.JF02283}attP2

Egfr^JF02384

P{TRiP.JF02384}

y¹ v¹; P{TRiP.JF02384}attP2

Egfr^{FRT.RNAi.slbo}

M{slbo(FRT.lacZ)Egfr.RNAi}

w¹¹¹⁸; M{slbo(FRT.lacZ)Egfr.RNAi}ZH-51D

Egfr^RNAi.slbo

M{slbo(-FRT)Egfr.RNAi}

Egfr^HMS05003

P{TRiP.HMS05003}

y¹ v¹; P{TRiP.HMS05003}attP40

mir-10^HMS01427

P{TRiP.HMS01427}

y¹ sc^* v¹ sev²¹; P{TRiP.HMS01427}attP2

Selected Drosophila classical alleles

Allele

Allele class

Mutagen

Publicly Available Stocks

Egfr^top-EB

loss of function allele

ethyl methanesulfonate

Egfr^f24

loss of function allele

ethyl methanesulfonate

w^*; smo^D16 P{neoFRT}42D mam¹⁰ Egfr^f24/CyO, P{ActGFP}JMR1

Egfr^f36

amorphic allele - genetic evidence

gamma ray

Egfr^top-101

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^top-EE42

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^top-EC20

loss of function allele

ethyl methanesulfonate

Egfr^f3

loss of function allele

ethyl methanesulfonate

cn¹ Egfr^f3 bw¹ speck¹/CyO

Egfr^f6

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^f9

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^f11

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^top-EA

loss of function allele

ethyl methanesulfonate

Egfr^top-CA

loss of function allele

ethyl methanesulfonate

Egfr^top-38

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^f8

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^JE1

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^f38

amorphic allele - genetic evidence

gamma ray

Egfr^JE13

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^f12

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^f10

amorphic allele - genetic evidence

ethyl methanesulfonate

Egfr^f5

amorphic allele - genetic evidence

ethyl methanesulfonate

cn¹ Egfr^f5 bw¹ speck¹/CyO

Egfr^top-18A

amorphic allele - genetic evidence

Egfr^f37

amorphic allele - genetic evidence

gamma ray

Egfr^t1

ethyl methanesulfonate

Egfr^t1 bw¹/CyO

Egfr^f2

amorphic allele - genetic evidence

ethyl methanesulfonate

cn¹ Egfr^f2 bw¹ speck¹/CyO

mir-375^KO

amorphic allele - molecular evidence

ends-out gene targeting

w^*; TI{GAL4}mir-375^KO/CyO, P{GAL4-twi.G}2.2, P{UAS-2xEGFP}AH2.2

mir-10^KO

amorphic allele - molecular evidence

ends-out gene targeting

w^*; TI{GAL4}mir-10^KO

mir-8^Δ2

amorphic allele - molecular evidence

Delta2-3 transposase

w^*; mir-8^Δ2/CyO, P{GAL4-Kr.C}DC3, P{UAS-GFP.S65T}DC7

mir-8^SC1

mir-8^Δ

amorphic allele - molecular evidence

FLPase

P-element activity

P-element activity

Delta2-3 transposase

amorphic allele - genetic evidence

Delta2-3 transposase

References (21)

Report Sections

Open Close